• Citer

Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe.

par Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE), Fumiyo;Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Group, Rebecca;Nakagawa, Dominique;Lodwick, Ard;Costagliola, Carlo;van Sighem, Daniel;Torti, Amanda;Podzamczer, Bruno;Mocroft, Maria;Ledergerber, Alessandra;Dorrucci, Klaus;Cozzi-Lepri, Bernard;Jansen, Federico;Masquelier, Stéphane;Garcia Colominas, Christoph ;De Wit, Niels ;Stephan, Gerd;Obel, Antonella;Fätkenhaeuer, Hellen;Castagna, Cristina;Sambatakou, Jade;Mussini, Robert;Ghosn, Xavier;Zangerle, Laurence;Duval, Santiago;Meyer, Céline;Pérez-Hoyos, Jesper;Fabre-Colin, Geneviève;Kjaer, Jesper;Chêne, Andrew;Grarup, ;Phillips,
Référence Journal of acquired immune deficiency syndromes, 59, 3, page (294-299)
Publication Publié, 2012-03

Article révisé par les pairs

• Détails
• Contenu

Résumé :

Despite the increasing success of antiretroviral therapy (ART), virologic failure of the 3 original classes [triple-class virologic failure, (TCVF)] still develops in a small minority of patients who started therapy in the triple combination ART era. Trends in the incidence and prevalence of TCVF over calendar time have not been fully characterised in recent years.